Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Yasuto Yoneshima, Isamu Okamoto, Tomotsugu Takano, Aimi Enokizu, Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

Original languageEnglish
Pages (from-to)349-351
Number of pages3
JournalLung Cancer
Issue number3
Publication statusPublished - Jun 1 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Successful treatment with alectinib after crizotinib-induced esophageal ulceration'. Together they form a unique fingerprint.

Cite this